Jun 2026 (Q2 FY26) — Aug 6, 2026
Zoetis Q2 FY26 — Companion Animal Pressure Offsets Livestock Strength; Full-Year Outlook Revised Down
Read the full callZoetis (ZTS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Zoetis earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 2,468 | −0.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | 691 | −4.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
8 of 8 judged targets kept · 17 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| FY26 adjusted diluted EPS guidance | $7.00 to $7.10 | Dec 2025 | We now expect adjusted diluted EPS of $6.15 to $6.25 and reported diluted EPS of $5.55 to $5.65 | Revised Down |
| FY26 livestock organic operational growth guidance | Mid-single-digit organic operational livestock revenue growth | Dec 2025 | there are strong fundamentals here that we believe to be sustainable, likely in the mid- to high single-digit range when we look at this year | On Track |
| Lenivia and Portela commercial launch timing | Commercial launch of Lenivia (dog) and Portela (cat) long-acting OA pain products in the first half of 2026 | Sep 2025 | we did get approval in the -- in certain markets in the EU and in Canada, and we just launched that product | Achieved |
17 of Zoetis Inc.'s 25 targets are still open. See which are on track and which have gone quiet. The 3 above are the free sample; 22 more targets are in the full ledger.
Claimed
- International revenue grew 6% organically, supported by broad-based growth in emerging markets.
- Livestock delivered strong 11% organic revenue growth, led by cattle and poultry.
- Companion Animal Diagnostics revenue grew 12% organically, reflecting sustained demand.
- Adjusted diluted EPS was $1.87, up 4% year-over-year, benefiting from share repurchases.
Qualified
- Organic operational revenue declined 1% in Q2 FY26.
- Adjusted net income declined 2% organically in Q2 FY26.
- U.S. revenue declined 7% organically, driven by Companion Animal pressure.
- Key Dermatology revenue declined 16% globally (18% in US) due to softer demand and intensified competition.
- Full-year organic operational revenue growth guidance revised to decline 3% to 1%.
- Full-year adjusted net income organic operational growth guidance revised to decline 9% to 5%.
Price
$79.59 +0.26% · +$0.21
Performance −44.8% 1Y
1Y: $144.06 on 17 Oct 2025 → $79.59. High $147.53 (27 Oct 2025), low $69.1 (1 Oct 2026).
- Previous close
- $79.38
- 52-week range
- $69.1 – $147.53
- One year
- −45.13%
Overview
- Symbol
- ZTS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
8 of 8 judged targets kept · 17 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| FY26 adjusted diluted EPS guidance | $7.00 to $7.10 | Dec 2025 | We now expect adjusted diluted EPS of $6.15 to $6.25 and reported diluted EPS of $5.55 to $5.65 | Revised Down |
| FY26 livestock organic operational growth guidance | Mid-single-digit organic operational livestock revenue growth | Dec 2025 | there are strong fundamentals here that we believe to be sustainable, likely in the mid- to high single-digit range when we look at this year | On Track |
| Lenivia and Portela commercial launch timing | Commercial launch of Lenivia (dog) and Portela (cat) long-acting OA pain products in the first half of 2026 | Sep 2025 | we did get approval in the -- in certain markets in the EU and in Canada, and we just launched that product | Achieved |
Claimed
- International revenue grew 6% organically, supported by broad-based growth in emerging markets.
- Livestock delivered strong 11% organic revenue growth, led by cattle and poultry.
- Companion Animal Diagnostics revenue grew 12% organically, reflecting sustained demand.
- Adjusted diluted EPS was $1.87, up 4% year-over-year, benefiting from share repurchases.
Qualified
- Organic operational revenue declined 1% in Q2 FY26.
- Adjusted net income declined 2% organically in Q2 FY26.
- U.S. revenue declined 7% organically, driven by Companion Animal pressure.
- Key Dermatology revenue declined 16% globally (18% in US) due to softer demand and intensified competition.
- Full-year organic operational revenue growth guidance revised to decline 3% to 1%.
- Full-year adjusted net income organic operational growth guidance revised to decline 9% to 5%.
The full ledger
Open Zoetis Inc.’s full ledger
A free account opens 5 company ledgers a month. All 25 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
Zoetis Q1 FY26 — U.S. companion animal slump forces guidance cut; livestock and International cushion
Read the full callDec 2025 (Q4 FY25) — Feb 12, 2026
Zoetis Q4 FY25 — Strong Operational Growth Driven by International Markets and Diverse Portfolio
Read the full callEvery analysed call
Zoetis earnings calls (ZTS)
Financials
What the filings say
Net profit, year on year: −5% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,388 | 2,317 | 2,198 | 2,474 | 2,400 | 2,387 | 2,262 | 2,468 |
| Other income | 16 | 20 | 15 | -2 | 13 | 9 | 20 | 5 |
| Interest | 57 | 51 | 54 | 53 | 58 | 57 | 62 | 61 |
| Profit before tax | 874 | 732 | 773 | 912 | 887 | 761 | 758 | 866 |
| Tax rate | 20.8% | 20.6% | 22.1% | 20.4% | 18.7% | 20.8% | 20.7% | 20.2% |
| Net profit | 682 | 581 | 602 | 726 | 721 | 603 | 601 | 691 |
| EPS ($ per share) | 1.51 | — | 1.34 | 1.63 | 1.63 | — | 1.42 | 1.65 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 3,270 | 4,427 | 5,659 | 7,186 | 8,668 | 10,295 | 11,968 | 13,798 |
| Total liabilities | 8,592 | 8,837 | 9,836 | 9,356 | 10,522 | 9,295 | 9,467 | 12,075 |
| Fixed assets | 1,658 | 1,940 | 2,202 | 2,422 | 2,753 | 3,204 | 3,391 | 3,693 |
| Investments | 99 | 0 | — | — | — | — | — | 0 |
| Total assets | 10,777 | 11,545 | 13,609 | 13,900 | 14,925 | 14,286 | 14,237 | 15,490 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,790 | 1,795 | 2,126 | 2,213 | 1,912 | 2,353 | 2,953 | 2,904 |
| Cash from investing | -2,259 | -504 | -572 | -458 | -883 | -777 | -315 | -748 |
| Cash from financing | 533 | -951 | 123 | -1,862 | -904 | -3,109 | -2,660 | -1,870 |
| Net cash flow | 38 | 332 | 1,670 | -119 | 96 | -1,540 | -54 | 325 |
| Capital expenditure | -338 | -460 | -453 | -477 | -586 | -732 | -655 | -621 |
| Free cash flow | 1,452 | 1,335 | 1,673 | 1,736 | 1,326 | 1,621 | 2,298 | 2,283 |
ZTS revenue by segment
United States shrank from 56% to 55% of revenue over the last two years.
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| United States | 56% | 54% | 53% | 55% | 55% | 52% | 48% | 51% | -6.6% |
| International | 43% | 45% | 45% | 44% | 44% | 47% | 51% | 48% | +9.6% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
ZTS operating KPIs by quarter
| KPI | Dec 2024 Q4 FY24 | Jun 2025 Q2 FY25 | Change vs prior quarter |
|---|---|---|---|
| Patients Librela | 1.2M+Librela, now entering its second year in the market, generated $53 million, growing 21% on the quarter and reaching more than 1.2 million patients.Source: earnings call transcript | 1MAnd today, we are reaching just 1 million of them.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q2 FY2026 · share of revenue
- US 51% ↓ 5 pt
- Other Emerging Markets 11% ↑ 2 pt
- Other Developed Markets 8% ↑ 1 pt
- BR 4%
- AU 4%
- GB 3%
- CA 3%
- DE 3%
- CN 3%
- MX 2%
- ES 2%
- JP 2%
- IT 2%
- FR 2%
- CL 1%
As ZTS cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
86 filings between Feb 6, 2026 and Sep 30, 2026.
Open market
decisions to buy or sellPurchases
$886.4K
3 purchases by 3 insiders
Sales
$2.54M
2 sales by 1 insider
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 42
- Option exercise — converted options into shares
- 30
- Tax withheld — shares kept back by the company to cover tax
Also filed: 6 other filings, 3 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| PECK KRISTIN C | — | $2.54M | Feb 17, 2026 |
| DAMELIO FRANK A | $501.3K | — | May 13, 2026 |
| MCCALLISTER MICHAEL B | $233.3K | — | May 11, 2026 |
| BISARO PAUL | $151.8K | — | May 13, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | FULLER JULIE Executive Vice President | Tax withheld | 274 | $19.1K |
| Sep 30, 2026 | FULLER JULIE Executive Vice President | Option exercise | 799 | — |
| Aug 7, 2026 | DAMELIO FRANK A Director | Gift | 6,650 | $0 |
| Jun 10, 2026 | MCCALLISTER MICHAEL B Director | Gift | 1,209 | $0 |
| May 21, 2026 | Stetter Mark Director | Option exercise | 1,572 | — |
| May 20, 2026 | PARENT LOUISE M Director | Option exercise | 10,186 | — |
| May 20, 2026 | PARENT LOUISE M Director | Option exercise | 1,944 | — |
| May 13, 2026 | BISARO PAUL Director | Purchase | 2,000 | $151.8K |
| May 13, 2026 | DAMELIO FRANK A Director | Purchase | 6,650 | $501.3K |
| May 11, 2026 | MCCALLISTER MICHAEL B Director | Purchase | 3,000 | $233.3K |
| Apr 30, 2026 | Esch Kevin Executive Vice President | Tax withheld | 75 | $8.6K |
| Apr 30, 2026 | Esch Kevin Executive Vice President | Option exercise | 259 | — |
| Mar 31, 2026 | Sarbaugh Keith Executive Vice President | Option exercise | 1,528 | — |
| Mar 31, 2026 | Sarbaugh Keith Executive Vice President | Tax withheld | 524 | $61.9K |
| Mar 9, 2026 | Norden Gregory Director | Gift | 1,213 | $0 |
| Feb 19, 2026 | Lagano Roxanne Executive Vice President | Option exercise | 750 | — |
| Feb 19, 2026 | Esch Kevin Executive Vice President | Tax withheld | 35 | $4.5K |
| Feb 19, 2026 | Esch Kevin Executive Vice President | Option exercise | 102 | — |
| Feb 19, 2026 | Brannan Jamie Executive Vice President | Option exercise | 1,204 | — |
| Feb 19, 2026 | Sarbaugh Keith Executive Vice President | Tax withheld | 154 | $19.6K |
| Feb 19, 2026 | Sarbaugh Keith Executive Vice President | Option exercise | 386 | — |
| Feb 19, 2026 | Reed Willie M Director | Option exercise | 1,619 | — |
| Feb 19, 2026 | Driscoll Rimma Executive Vice President | Tax withheld | 179 | $22.8K |
| Feb 19, 2026 | PARENT LOUISE M Director | Option exercise | 1,619 | — |
| Feb 19, 2026 | Norden Gregory Director | Option exercise | 1,619 | — |
| Feb 19, 2026 | Brannan Jamie Executive Vice President | Tax withheld | 566 | $72.0K |
| Feb 19, 2026 | Driscoll Rimma Executive Vice President | Option exercise | 454 | — |
| Feb 19, 2026 | Broadhurst Vanessa Director | Option exercise | 1,619 | — |
| Feb 19, 2026 | FULLER JULIE Executive Vice President | Option exercise | 750 | — |
| Feb 19, 2026 | Lagano Roxanne Executive Vice President | Tax withheld | 258 | $32.8K |
| Feb 19, 2026 | Ferran Astorga Jeannette Executive Vice President | Tax withheld | 190 | $24.2K |
| Feb 19, 2026 | Ferran Astorga Jeannette Executive Vice President | Option exercise | 431 | — |
| Feb 19, 2026 | Leatherberry Antoinette Renee Director | Other | 406 | $51.7K |
| Feb 19, 2026 | PECK KRISTIN C Chief Executive Officer | Tax withheld | 3,623 | $461.1K |
| Feb 19, 2026 | PECK KRISTIN C Chief Executive Officer | Option exercise | 7,354 | — |
| Feb 19, 2026 | Leatherberry Antoinette Renee Director | Option exercise | 1,619 | — |
| Feb 19, 2026 | Joseph Wetteny Chief Financial Officer | Option exercise | 2,050 | — |
| Feb 19, 2026 | Joseph Wetteny Chief Financial Officer | Tax withheld | 703 | $89.5K |
| Feb 19, 2026 | Ashton Nicholas Executive Vice President | Tax withheld | 392 | $49.9K |
| Feb 19, 2026 | FULLER JULIE Executive Vice President | Tax withheld | 290 | $36.9K |
| Feb 19, 2026 | Ashton Nicholas Executive Vice President | Option exercise | 750 | — |
| Feb 19, 2026 | Broadhurst Vanessa Director | Other | 517 | $65.8K |
| Feb 19, 2026 | Hattersley Gavin Director | Other | 481 | $61.2K |
| Feb 19, 2026 | Norden Gregory Director | Other | 406 | $51.7K |
| Feb 19, 2026 | MCCALLISTER MICHAEL B Director | Option exercise | 1,619 | — |
| Feb 19, 2026 | MCCALLISTER MICHAEL B Director | Other | 413 | $52.6K |
| Feb 19, 2026 | Hattersley Gavin Director | Option exercise | 1,619 | — |
| Feb 19, 2026 | BISARO PAUL Director | Option exercise | 1,619 | — |
| Feb 19, 2026 | PARENT LOUISE M Director | Other | 615 | $78.3K |
| Feb 17, 2026 | PECK KRISTIN C Chief Executive Officer | Sale 10b5-1 plan | 10,800 | $1.38M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Zoetis Inc.
Free account. Everything above stays public.
Write why you follow Zoetis Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading